Striatal dopamine transporter binding does not correlate with clinical severity in dementia with lewy bodies

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1072-1076

  Ziebell, Morten ^a   Andersen, Birgitte B ^a   Pinborg, Lars H ^a   Knudsen, Gitte M ^a   Stokholm, Jette ^a   Thomsen, Gerda ^a   Karlsborg, Merete ^b   Høgh, Peter ^c   Mørk, Mette Louise ^a   Hasselbalch, Steen G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

DLB; Dopamine transporter; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; N (3 IODOPROP 2E ENYL) 2 BETA CARBOMETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HALLUCINATION; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BINDING; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DLB; DOPAMINE TRANSPORTER; SPECT;

AGED; BIOLOGICAL MARKERS; BRAIN; CORPUS STRIATUM; DENMARK; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; NORTROPANES; PREVALENCE; PROTEIN BINDING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 84879967627     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.114025     Document Type: Article

References (37)

1. Tofaris GK, Spillantini MG. Alpha-synuclein dysfunction in Lewy body diseases. Mov Disord. 2005;20(suppl 12):S37-S44.
2. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65: 1863-1872.
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415-455.
4. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
5. Sossi V, Dinelle K, Topping GJ, et al. Dopamine transporter relation to levodopaderived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem. 2009;109:85-92.
6. Ashkan K, Wallace BA, Mitrofanis J, et al. SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease. Parkinsonism Relat Disord. 2007;13:266-275.
7. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci. 2001;21:6853-6861.
8. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692-698.
9. Walker Z, Costa DC,Walker RW, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62: 1568-1572.
10. Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002;29:615-622.
11. Burruss JW, Hurley RA, Taber KH, Rauch RA, Norton RE, Hayman LA. Functional neuroanatomy of the frontal lobe circuits. Radiology. 2000;214:227-230.
12. Roselli F, Pisciotta NM, Perneczky R, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123I-FPCIT SPECT study. Mov Disord. 2009;24:2097-2103.
13. Ziebell M, Holm-Hansen S, Thomsen G, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51:1885-1891.
14. Ziebell M, Andersen BB, Thomsen G, et al. Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms. Eur J Nucl Med Mol Imaging. 2012;39:242-250.
15. Pinborg LH, Ziebell M, Frokjaer VG, et al. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med. 2005;46:1119-1127.
16. Ziebell M, Pinborg LH, Thomsen G, et al. MR imaging-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study. J Nucl Med Technol. 2010;38: 61-68.
17. Ziebell M, Thomsen G, Knudsen GM, et al. Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging. 2007;34:101-109.
18. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
19. Thomsen G, Ziebell M, Jensen PS, Knudsen GM, Pinborg LH. No correlation between body mass index and striatal dopamine transporter availability in healthy volunteers using SPECT and [123I]PE2I. Obesity (Silver Spring). In press.
20. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746.
21. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67:1931-1934.
22. Song IU, Kim YD, Cho HJ, Chung SW, Chung YA. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord. 2013;27:51-55.
23. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges Jr. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology. 2000;55:1613-1620.
24. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord. 2003;18(suppl 7):S63-S70.
25. Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a crosssectional comparative study. Mov Disord. 2003;18:884-889.
26. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol. 1997;41: 368-374.
27. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
28. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231-237.
29. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738-750.
30. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387-392.
31. Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav. 2001;70:571-579.
32. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62: 181-187.
33. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6:358-370.
34. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry. 2000;177:252-256.
35. Farina E, Baglio F, Caffarra P, et al. Frequency and clinical features of Lewy body dementia in Italian memory clinics. Acta Biomed. 2009;80:57-64.
36. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60: 1586-1590.
37. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176-1181.